

Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers

Horizon Europe

CODICE	AMBITO
HORIZON-MISS-2026-02-CANCER-03	Internazionale
LOCALITÀ	STATO
Europa	Aperto
PROGRAMMA	CURATO DA
Horizon Europe	Maria Macedo
GENERATO IL	
13 giugno 2026	

Dettagli Finanziari

TIPO DI SUPPORTO	TASSO MASSIMO DI FINANZIAMENTO
Contributo a Fondo Perduto	100%
BUDGET	VALORE DI PROGETTO AMMISSIBILE
22.2M€	Up to 8M€
DURATA MASSIMA	
60 mesi	

Date e Scadenze

DATA DI PUBBLICAZIONE

Non definita

DATA DI APERTURA

10 febbraio 2026

Fasi di Candidatura

- Deadline: 15 settembre 2026 alle ore 16:00 (95 giorni rimanenti)

Obiettivi

Objectives

This incentive is part of the Horizon Europe framework and is aligned with missions focusing on cancer research and related innovations. It aims to support eligible organizations across Europe, including research institutions, universities, public and private entities, and consortia that can deliver solutions advancing the fight against cancer. The incentive targets advancements in prevention, diagnosis, treatment, and patient care by fostering collaboration at the European level. Eligible companies are those that can demonstrate expertise and the capacity to contribute to impactful R&I in the oncology field and support the objectives outlined by Horizon Europe and the EU's Cancer Mission.

Funding

The funding from Horizon Europe is generally provided as non-refundable grants. The maximum funding rate for eligible entities under Horizon Europe Research and Innovation Actions can reach up to 100% for non-profit entities and 70% for commercial entities, including indirect costs calculated at a flat rate. Budget limits and minimum or maximum project values are defined by the specific topic and work programme, with typical EU contribution guidelines provided for each call. The total call budget and upper/lower project amounts will be provided in the Work Programme or topic description on the Funding & Tenders Portal. Applicants should carefully consult these documents to determine the eligibility of their cost structures and financial needs.

Spese Ammissibili

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

Idoneità

Settori Idonei

- Salute e Life Sciences

Dimensioni Aziendali

- Micro
- PMI

- Small Mid-Cap
- Mid-Cap
- Grande
- Enti privati non profit
- Enti pubblici

Modalità di Candidatura

- Consorzio / Co-promozione

Dettagli Programma UE

ID BANDO	PROGETTI PREVISTI
HORIZON-MISS-2026-02-CANCER-03	3

Link Ufficiali

Regolamento Ufficiale:

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2026-02-CANCER-03?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&isExactMatch=true&status=31094501,31094502&programmePart=43108557&frameworkProgramme=43108390&deadlineDate=1780182000000,1798675200000>

Pagina Grantavia: <https://grantavia.com/it/incentives/pragmatic-clinical-trials-to-optimise-immunotherapeutic-interventions-for-patients-with-refractory-cancers>

Prenota un incontro: <https://calendly.com/ines-carreira-fi-group/reuniao>